Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Arcturus Therapeutics reported a decrease in total assets from $271.1 million at the end of 2025 to $215.3 million as of September 30, 2026, primarily driven by a reduction in cash and cash equivalents. The company's forward-looking statements highlight the termination of the CSL Collaboration Agreement and plans to advance its therapeutics pipeline, including ARCT-810 and ARCT-032, independently or with other partners.
Nelnet reported Q3 2026 GAAP net income of $76.2 million, or $2.13 per share, down from $106.7 million in the prior year. The company saw growth in its consumer loan portfolio to $1.30 billion and acquired $3.23 billion in consumer loans during the quarter, though results were impacted by a $34.5 million provision for loan losses.
Term
Q3 2026
“We delivered strong operating performance this quarter, with continued progress diversifying our products and customer base. We increased our dividend and continued to repurchase shares, while remaining focused on investing in our businesses and creating long-term value.”
American Water Works Company reported Q3 2026 financial results with operating revenues of $1.51 billion and net income of $387 million. The company demonstrated growth in its regulated business segment, with property, plant, and equipment increasing to $40.5 billion as of September 30, 2026.
TSS, Inc. reported total revenues of $50.1 million for the third quarter of 2026, driven by significant growth in system integration services related to AI technologies. Despite a decrease in procurement revenue compared to the prior year, the company achieved a net income of $1.15 million for the quarter, rebounding from a net loss in the same period of 2025.
Karman Holdings Inc. reported record Q3 2026 financial results with revenue of $202 million, representing 66% total growth year-over-year. The company achieved record net income of $21 million and increased its full-year 2026 revenue outlook to a range of $755 million to $760 million.
Term
Q3 2026
“We delivered another quarter of record results, highlighted by 66% total revenue growth, 25% organic revenue growth, 60% adjusted EBITDA growth, $13 million of free cash flow, and a doubling of backlog compared to fiscal year-end 2025.”
Jon Rambeau, Chief Executive Officer of Karman Space & Defense
“The award of our second long-term agreement in the quarter further extends our planning horizon and enables us to allocate capital and resources more efficiently.”
Jon Rambeau, Chief Executive Officer of Karman Space & Defense
VIAVI Solutions reported a significant increase in total net revenue to $469.3 million for the quarter ended October 3, 2026, compared to $299.1 million in the prior year. The company swung to a net income of $76.0 million from a net loss of $21.4 million, driven by strong product revenue growth and improved operating margins.
American Healthcare REIT reported Q3 2026 net income of $31.2 million and increased its full-year NFFO guidance to $2.23-$2.26 per share. The company achieved 13.8% same-store NOI growth and completed approximately $2.07 billion in new investments year-to-date, primarily in its senior housing operating properties segment.
Term
Q3 2026
“We strengthened three things this quarter: the team, the portfolio and the platform that connects them. We added executive leadership across finance, asset management, and technology, added nearly $2.1 billion of new investments in 2026, and brought new operating partners onto a platform that pairs their local expertise with portfolio-wide collaborations among the top operators in the senior housing industry. Importantly, this growth has been ambitious but disciplined. Superior care quality drives resident outcomes, and resident outcomes drive our performance. Our goal remains to be the”
Jeff Hanson, the Company’s Chairman and Chief Executive Officer
Funko reported Q3 2026 financial results with net sales increasing 3% to $258.3 million, driven by 4.8% growth in its Core Collectibles category. The company achieved a significant increase in net income to $7.5 million compared to $0.9 million in the prior year and reiterated its full-year 2026 guidance for net sales and Adjusted EBITDA.
Term
Q3 2026
“Q3 was another strong quarter for Funko, marked by net sales growth, continued gross margin strength and adjusted EBITDA above guidance, demonstrating that we are building a more focused and profitable business.”
Josh Simon, Chief Executive Officer of Funko, Inc.
“Core Collectibles grew nearly 5%, with international markets again a source of strength. The quarter provides further evidence that Make Culture Pop! is becoming a more deliberate and disciplined growth engine.”
Josh Simon, Chief Executive Officer of Funko, Inc.
RenovoRx reported record third-quarter 2026 revenue exceeding $1 million, representing a four-fold increase year-over-year. The company expanded its active commercial cancer center customer base to 26 and reaffirmed its full-year 2026 revenue guidance of $3.75 million to $4.25 million.
Term
Q3 2026
“We generated record results in the third quarter as revenue exceeded the million-dollar threshold and we continued to deliver on all three of our core priorities.”
Shaun Bagai, Chief Executive Officer of RenovoRx
“Looking ahead, given the strong momentum, we continue to expect full-year 2026 revenue for RenovoCath in the range of $3.75 million to $4.25 million, which would more than triple 2025 revenue at the midpoint.”
Moelis & Company reported record revenues for the first nine months of 2026, with Q3 adjusted revenues rising 13% year-over-year to $425.6 million. The firm declared a quarterly dividend of $0.65 per share and highlighted significant talent expansion with 13 Managing Directors joining year-to-date and 11 more committed to join.
Term
Q3 2026
“We reported record revenues for the first nine months of the year, reflecting continued momentum across our business and the strength of our expanded platform. With a record pipeline, strong levels of client activity, and continued investments in exceptional talent, we are well positioned to capitalize on attractive growth opportunities and deliver long-term value for our clients and shareholders”
Navid Mahmoodzadegan, Chief Executive Officer and Co-Founder
Live Nation reported record third-quarter results with revenue increasing 19% to $10.1 billion and fan attendance growing 19% to 61 million. The company is on track for a record year, having already sold 170 million tickets through October, surpassing the total for all of 2025.
Term
Q3 2026
“In a world of endless screens and AI-generated everything, the one thing that can't be replicated is being there. Artists are taking their music to more fans in more places than ever, and fans are showing up in record numbers. Through October, we've sold 170 million tickets, up 13% and already ahead of all of last year. We now expect to welcome nearly 180 million fans in 2026.”
Michael Rapino, President and CEO
“With double-digit adjusted operating income (AOI) growth across all three segments this quarter, we're on track to deliver another record year and sustain double-digit growth for years to come.”
LB Pharmaceuticals reported third quarter 2026 financial results, highlighting a cash position of $403.8 million following a $150 million private placement. The company remains on track for a Phase 3 topline data readout for its lead schizophrenia candidate, LB-102, in the first half of 2027.
“We recently strengthened our leadership team with the appointments of Dr. Susan Kozauer as Chief Medical Officer and Joe Miller as Chief Financial Officer, adding two highly accomplished executives whose expertise is directly aligned with our next phase of growth as we advance LB-102 across multiple neuropsychiatric indications and prepare for potential commercialization in schizophrenia.”
Heather Turner, Chief Executive Officer of LB Pharmaceuticals
“Our recent R&D Day highlighted why we believe LB-102 has the potential to become the branded antipsychotic of choice, based on a differentiated profile with the potential to balance efficacy, tolerability, and simplicity of use.”
Heather Turner, Chief Executive Officer of LB Pharmaceuticals
Athene Holding Ltd. reported a net loss of $1.1 billion for the quarter ended September 30, 2026, driven by significant investment-related losses and a sharp decline in accumulated other comprehensive income. Despite the quarterly loss, total assets grew to $477.6 billion, and net investment income remained strong at $5.3 billion for the quarter.
Advanced Drainage Systems reported net sales of $1.89 billion for the six months ended September 30, 2026, an increase from $1.68 billion in the prior year period. Net income from continuing operations for the first half of fiscal 2027 reached $310.2 million, supported by a gross profit of $753.9 million despite rising selling, general, and administrative expenses.
Atlanticus Holdings Corp reported Q3 2026 net income of $241.4 million, a significant increase from $209.6 million in the prior year period. The company's loan portfolio at fair value reached $6.68 billion, supported by a diverse range of senior notes and variable interest entity structures with maturities extending through 2033.
AMN Healthcare reported third quarter 2026 revenue of $717 million, a 13% year-over-year increase, driven by strong demand in travel nursing and allied staffing. GAAP net income reached $33 million ($0.83 per diluted share), while adjusted EBITDA grew 63% to $94 million. The company noted that results exceeded guidance due to volume growth and the release of labor disruption reserves.
Term
Q3 2026
“We are encouraged by the continued growth in nursing and allied staffing. Demand strengthened during the third quarter and through October and our team is delivering for our clients through faster recruiting, automation, and around-the-clock execution. We also are making progress on improvements in our other segments.”
Cary Grace, President and Chief Executive Officer
“Healthcare organizations increasingly want better visibility and more strategic management of their total workforce. Our strategy to bring together our talent engagement, trusted client relationships, operational expertise, and technology-enabled solutions is well-timed with the marketplace’s demands.”
For the three months ended September 30, 2026, Ardent Health reported total revenue of $1.62 billion and net income attributable to the company of $44.5 million, a significant recovery from a net loss of $23.5 million in the prior year period. For the nine-month period, net income reached $101.3 million, supported by a decrease in salaries and benefits expenses and the absence of debt extinguishment losses seen in 2025.
Dentsply Sirona reported Q3 2026 net sales of $836 million, a 7.6% decrease year-over-year, and a GAAP diluted loss per share of $0.01. Despite challenging industry conditions, the company highlighted record quarterly sales for its Wellspect Healthcare segment and updated its full-year 2026 outlook.
Term
Q3 2026
“We continued to make progress on our Return-to-Growth Action Plan in the third quarter despite challenging industry-wide conditions. We are seeing encouraging signs of progress, including record quarterly sales for Wellspect Healthcare, progress in priority areas of implants and endodontics, and broader customer access through our expanded U.S. dealer network. Building on the investments we began in the first half, our focus is now on execution, putting our sales force, clinical education and innovation capabilities to work to drive consistent performance and sustainable growth.”
Dan Scavilla, President and Chief Executive Officer
Willdan Group reported Q3 2026 financial results with contract revenue increasing 17.9% to $214.5 million, though net income decreased 13.6% to $11.9 million. The company raised its FY2026 guidance and introduced preliminary FY2027 targets, expecting to cross the $1 billion revenue threshold following its acquisition of Mantis Innovation.
Term
Q3 2026
“We delivered strong operational performance in the third quarter of 2026. Net revenue grew 18% and adjusted EBITDA margin expanded to 25.2% in the quarter. We also closed the Mantis Innovation acquisition, the largest in our history, expanding our energy management services for commercial and industrial customers. Given our strong results and visibility, we are raising our FY2026 targets and are introducing preliminary FY2027 targets in advance of our formal outlook in late February. We are executing well and our markets are strong. Willdan is well positioned to cross the $1 billion revenue threshold and grow adjusted EBITDA by more than 25 percent in FY2027.”
Mike Bieber, Willdan’s President and Chief Executive Officer
DXP Enterprises reported third quarter 2026 sales of $587.2 million, a 14.3% increase year-over-year, and GAAP diluted EPS of $1.64. The company achieved record sales driven by organic growth and the contribution of five acquisitions completed through the first nine months of the year. Adjusted EBITDA rose 19.0% to $67.3 million, reflecting sustained margin strength across its Service Centers and Innovative Pumping Solutions segments.
Term
Q3 2026
“DXP delivered a strong third quarter, with sales of $587.2 million, diluted earnings per share of $1.64, Adjusted EBITDA of $67.3 million, and free cash flow of $14.4 million. Our results reflect continued execution of our growth strategy, solid organic performance, contribution from recent acquisitions, and sustained strength in EBITDA margins.”
David R. Little, Chairman and Chief Executive Officer
“Our third quarter sales and adjusted EBITDA continue to show strength and resilience as we march upwards and set a new sales high watermark. Specifically, this quarter reflects continued execution of our strategic goals and the confidence we have in our balanced mix of business, tremendous teams, and a strong balance sheet to support our key initiatives.”
Kent Yee, Chief Financial Officer and Senior Vice President
Opendoor Technologies reported Q3 2026 revenue of $1.02 billion, a 12% increase year-over-year, driven by a significant surge in home acquisition volume. The company more than quadrupled its homes purchased to 4,865 units and reported a 57% improvement in marketing efficiency per acquired home.
Term
Q3 2026
“It’s been one year since we embarked on Opendoor 2.0 and I’m more confident in this company today than I was a year ago. We’re building a stronger, more capable company for the long term.”
Kaz Nejatian, CEO of Opendoor
“A year ago, conventional wisdom was that Opendoor couldn’t grow without overpaying, couldn’t operate more efficiently and couldn’t use less capital per acquisition. Our progress tells a different story.”
Applied Optoelectronics reported a net income of $6.3 million for the third quarter of 2026, a significant improvement from a net loss of $17.9 million in the prior year period, driven by a 127% increase in revenue to $269.9 million. Despite the quarterly profit, the company recorded a net loss of $30.8 million for the first nine months of 2026, while significantly increasing its cash position to $605.4 million following a large public offering of common stock.
Park National Corporation reported total assets of $12.33 billion as of September 30, 2026, reflecting significant growth from $9.59 billion at year-end 2025, driven largely by the acquisition of First Citizens. Net loans increased to $9.66 billion, while the allowance for credit losses rose to $109.9 million to account for the expanded portfolio and economic conditions.
Organogenesis Holdings Inc. reported a significant decline in net product revenue to $45.5 million for the quarter ended September 30, 2026, compared to $150.5 million in the prior year. The company experienced a net loss of $29.6 million for the quarter and $179.1 million for the nine-month period, driven by lower sales and a $30.1 million income tax expense related to the valuation of deferred tax assets.
For the nine months ended September 30, 2026, CVRx reported revenue of $44.3 million, an increase from $40.6 million in the prior year period. Despite the revenue growth, the company reported a net loss of $41.3 million for the first nine months of 2026, consistent with the prior year, as it continues to invest heavily in selling, general, and administrative expenses to support its Barostim product.
HCI Group reported a significant increase in net income to $230.7 million for the nine months ended September 30, 2026, compared to $201.4 million in the prior year period. Total revenue grew to $734.4 million, driven by higher net premiums earned and investment income, while total assets increased to $2.71 billion.
Devon Energy reported Q3 2026 financial results, generating $2.8 billion in operating cash flow and $2.0 billion in adjusted free cash flow. The company highlighted its pending $4.2 billion divestiture of Eagle Ford assets and raised its year-end 2026 synergy run rate target to $350 million. Devon also announced an initial 2027 outlook projecting 1-3% oil production growth with a capital budget of approximately $5.3 billion.
Term
Q3 2026
“The shareholder letter, supplemental financial tables, and forward-looking guidance are available on the company’s website at www.devonenergy.com.”
For the nine months ended September 30, 2026, Kayne DL 2021, Inc. reported total investment income of $25.9 million and net investment income of $23.3 million. The company experienced a net decrease in net assets of $2.4 million during the period, primarily driven by $6.1 million in realized and unrealized losses and $23.1 million in stockholder dividends.
Liberty Media reported total revenue of $1,226 million for the quarter ended September 30, 2026, driven entirely by Motorsport revenue following the discontinuation of other operations. Net earnings attributable to Liberty stockholders rose significantly to $163 million for the quarter, compared to $13 million in the prior year period.
Quantum-Si reported third quarter 2026 revenue of $212,000, reflecting a transition period as the company prepares for the commercial launch of its Proteus platform in Q2 2027. The company updated its full-year 2026 guidance to reflect lower operating expenses and cash usage, while reaffirming its cash runway into the fourth quarter of 2028.
“We made significant progress during the third quarter as we continued to advance Proteus toward commercial launch. Based on recent performance data, we believe we have substantially addressed the instrument variability issues identified earlier in development, and design activities for our additional instrument cycle are now complete.”
Jeff Hawkins, President and Chief Executive Officer
“At World HUPO, we demonstrated that Proteus significantly outperformed Platinum Pro across key measures of sequencing performance. While we are encouraged by these results, we believe the Proteus platform we ultimately launch will meaningfully exceed the performance demonstrated in this interim study.”
Jeff Hawkins, President and Chief Executive Officer